DNA sequencing by mass spectrometry

• US 5,691,141 A
• Filed: 06/06/1995
• Issued: 11/25/1997
• Est. Priority Date: 01/07/1993
• Status: Expired due to Term

• Current Assignee: Agena Bioscience Inc. (Mesa Laboratories Inc.)
• Original Assignee: Sequenom Incorporated (Laboratory Corporation Of America Holdings)
• Inventors: Koster, Hubert
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): TRAN, PAUL
• Application Number:
  US08/470,123
• Time in Patent Office: 903 Days
• Field of Search: 435/6, 435/91.1, 435/810, 536/24.33, 536/25.3, 536/25.4, 935/77, 935/78, 436/173, 436/174
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6872 involving mass spectrometry
• CPC Class Codes: C12Q 2537/113 Heteroduplex formation
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
• CPC Class Codes: C12Q 2563/167 Mass label
• CPC Class Codes: C12Q 2565/627 being a mass spectrometer
• CPC Class Codes: G01N 35/1067 for transfer to or from containers having different spacing
• CPC Class Codes: Y10S 435/81 Packaged device or kit
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
• CPC Class Codes: Y10T 436/25 including sample preparation

Abstract

The invention describes a new method to sequence DNA. The improvements over the existing DNA sequencing technologies are high speed, high throughput, no electrophoresis and gel reading artifacts due to the complete absence of an electrophoretic step, and no costly reagents involving various substitutions with stable isotopes. The invention utilizes the Sanger sequencing strategy and assembles the sequence information by analysis of the nested fragments obtained by base-specific chain termination via their different molecular masses using mass spectrometry, as for example, MALDI or ES mass spectrometry. A further increase in throughput can be obtained by introducing mass-modifications in the oligonucleotide primer, chain-terminating nucleoside triphosphates and/or in the chain-elongating nucleoside triphosphates, as well as using integrated tag sequences which allow multiplexing by hybridization of tag specific probes with mass differentiated molecular weights.

Claims

1. A kit for sequencing one or more species of nucleic acids by multiplex mass spectrometric nucleic acid sequencing, comprising:

a) a solid support having a linking functionality (L'"'"');

b) a set of nucleic acid primers suitable for initiating synthesis of a set of nucleic acids which are complementary to the different species of nucleic acids, the primers each including a linking group (L) able to interact with the linking functionality (L'"'"') and reversibly link the primers to the solid support and optionally, a tag probe;

c) a set of chain-elongating nucleotides for synthesizing the complementary nucleic acids;

d) a set of chain-terminating nucleotides for terminating synthesis of the complementary nucleic acids and generating sets of base-specific terminated complementary nucleic acid fragments; and

e) a polymerase for synthesizing the complementary nucleic acids from the nucleic acid primers, chain-elongating nucleotides and terminating nucleotides,

wherein in the absence of a tag probe, at least one reagent selected from the group consisting of the primers, the chain-elongating nucleotides, and the chain-terminating nucleotides is mass modified to provide distinction between each set of base-specifically terminated nucleotides of each species of nucleic acid by mass spectrometry.

2. A kit of claim 1, wherein the set of chain-elongating nucleotides is comprised of a nucleotide selected from the group consisting of deoxyadenosine triphosphate (dATP) deoxythymidine triphosphate (dTTP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP), deoxyinosine triphosphate (dITP), 7-deaza deoxyadenosine triphosphate (c⁷ dATP), 7-deaza deoxythymidine triphosphate (C⁷ TTP), 7-deaza deoxyguanosine triphosphate (c⁷ dGTP), 7-deaza deoxycytidine triphosphate (c⁷ dCTP) and 7-deaza deoxyinosine triphosphate (c⁷ dITP).

3. A kit of claim 1, wherein the set of chain-terminating nucleotides is comprised of the following nucleotides:

dideoxyadenosine triphosphate (ddATP), dideoxythymidine triphosphate (ddTTP), dideoxyguanosine triphosphate (ddGTP), dideoxycytidine triphosphate (ddCTP), 7-deaza dideoxyguanosine triphosphate (c⁷ ddGTP), 7-deaza dideoxyadenosine triphosphate (c⁷ ddATP), 7-deaza dideoxyinosine triphosphate (c⁷ ddITP).

4. A kit of claim 1, wherein the set of chain elongating nucleotides is comprised of a nucleotide selected from the group consisting of adenosine triphosphate (ATP), uridine triphosphate (UTP), guanosine triphosphate (GTP), cytidine triphosphate (CTP), inosine triphosphate (ITP), 7-deaza adenosine triphosphate (c⁷ ATP), 7-deaza guanosine triphosphate (c⁷ GTP), and 7-deaza inosine triphosphate (c⁷ ITP).

5. A kit of claim 1, wherein the set of chain elongating nucleotides is comprised of the following nucleotides:

deoxyadenosine triphosphate (3'"'"'-dATP), deoxyuridine triphosphate (3'"'"'-dUTP), deoxyguanosine triphosphate (3'"'"'-dGTP), deoxycytidine triphosphate (3'"'"'-dCTP), 7-deaza 3'"'"'deoxyadenosine triphosphate (c⁷ -3'"'"'dATP), 7-deaza 3'"'"'deoxyguanosine triphosphate (c⁷ -3'"'"'dGTP) and 7-deaza 3'"'"'deoxy o!inosine (c⁷ -3'"'"'dITP).

6. A kit of claim 1, wherein the linkage between the linking group (L) and the linking functionality (L'"'"') is selected from the group consisting of:

a photocleavable bond, a tritylether bond, a β

-benzoylpropionyl group, a levulinyl group, a disulfide bond, an arginine/arginine bond, a lysine/lysine bond, and a pyrophosphate bond and a bond created by Watson-Crick base pairing.

7. A kit of claim 1, wherein the mass modified reagent is modified with a mass-modifying functionality (M) at a heterocyclic base of at least one nucleotide.

8. The kit of claim 7, wherein the heterocyclic base-modified nucleotide is selected from the group consisting of a cytosine nucleotide modified at C-5, a thymine nucleotide modified at C-5, a thymine nucleotide modified at the C-5 methyl group, a uracil nucleotide modified at C-5, an adenine nucleotide modified at C-8, an adenine nucleotide modified at C-7, a c⁷ -deazaadenine modified at C-8, a c⁷ -deazaadenine modified at C-7, a guanine nucleotide modified at C-8, a guanine nucleotide modified at C-7, a c⁷ -deazaguanine modified at C-8, a c⁷ -deazaguanine modified at C-7, a hypoxanthine modified at C-8, a c⁷ -deazahypoxanthine modified at C-7, and a c⁷ -deazahypoxanthine modified at C-8.

9. A kit of claim 1, wherein the mass modified reagent is modified with a mass-modifying functionality (M) attached to one or more phosphate moieties of the internucleotidic linkages of the fragments.

10. A kit of claim 1, wherein the mass modified reagent is modified with a mass-modifying functionality (M) attached to one or more sugar moieties of nucleotides within the set of mass modified base-specifically terminated fragments at at least one sugar position selected from the group consisting of a C-2'"'"' position, an external C-3'"'"' position, and an external C-5'"'"' position.

11. A kit of claim 1, wherein the mass modified reagent is modified with a mass-modifying functionality (M) attached to the sugar moiety of a 5'"'"'-terminal nucleotide and wherein the mass-modifying function (M) is the linking functionality (L).

12. A kit of claim 1, wherein the base-specifically terminated nucleic acid fragments are generated using at least one reagent selected from the group consisting of a nucleic acid primer, a chain-elongating nucleotide, a chain-terminating nucleotide and a tag probe which has been modified with a precursor of the mass-modifying functionality, M;

and a subsequent step comprises modifying the precursor of the mass-modifying functionality, M, to generate the mass-modifying functionality, M, prior to mass spectrometric analysis.

13. A kit of claim 1, wherein the primer or the tag probe is comprised of a deoxyribonucleotide selected from the group consisting of:

a 7-deaza deoxyadenosine triphosphate, (c⁷ dA), a 7-deaza deoxyguanosine triphosphate (c⁷ dG) and a 7-deaza deoxyinosine triphosphate (c⁷ dI).

14. A kit of claim 1, wherein the primer or the tag probe is comprised of a ribonucleotide selected from the group consisting of:

7-deaza adenine (c⁷ A), 7-deaza guanine (c⁷ G) and 7-deaza inosine (c⁷ I).

15. A kit for sequencing nucleic acids by mass spectrometry, comprising:

a) a solid support having a linking functionality (L'"'"');

b) a set of nucleic acid primers suitable for initiating synthesis of a set of complementary nucleic acids which are complementary to the different species of nucleic acids, the primers each including a linking group (L) able to interact with the linking functionality (L'"'"') and reversibly immobilize the primers on the solid support;

c) a set of chain-elongating nucleotides for synthesizing the complementary nucleic acids;

d) a set of chain-terminating nucleotides for terminating synthesis of the complementary nucleic acids and generating sets of base-specific terminated complementary nucleic acid fragments; and

e) a polymerase for synthesizing the complementary nucleic acids from the primers, chain-elongating nucleotides and chain-terminating nucleotides,

wherein the chain-terminating nucleotides are mass-modified so that addition of one species of the chain-terminating nucleotides to the complementary nucleic acid can be distinguished by mass spectrometry from addition of all other species of chain-terminating nucleotides concurrently analyzed.

16. A kit of claim 15, wherein the set of chain-elongating nucleotides is comprised of a nucleotide selected from the group consisting of deoxyadenosine triphosphate (dATP) deoxythymidine triphosphate (dTTP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP), deoxyinosine triphosphate (dITP), a 7-deazadeoxyguanosine triphosphate (c⁷ dGTP), a 7-deazadeoxyadenosine triphosphate (c⁷ dATP), and a 7-deazadeoxyinosine triphosphate (c⁷ dITP).

17. A kit of claim 15, wherein the set of chain-terminating nucleotides is comprised of the following nucleotides:

dideoxyadenosine triphosphate (ddATP), dideoxythymidine triphosphate (ddTTP), dideoxyguanosine triphosphate (ddGTP), dideoxycytidine triphosphate (ddCTP), 7-deazadideoxyguanosine triphosphate (c⁷ ddGTP), 7-deazadideoxyadenosine triphosphate (c⁷ ddATP), 7-deazadideoxyinosine triphosphate (c⁷ ddITP).

18. A kit of claim 15, wherein the set of chain elongating nucleotides is comprised of a nucleotide selected from the group consisting of adenosine triphosphate (ATP), uridine triphosphate (UTP), guanosine triphosphate (GTP), cytidine triphosphate (CTP), inosine triphosphate (ITP), a 7-deazaadenosine triphosphate (c⁷ ATP), a 7-deazaguanosine triphosphate (c⁷ GTP), and a 7-deazainosine triphosphate (c⁷ ITP).

19. A kit of claim 15, wherein the set of chain terminating nucleotides is comprised of the following nucleotides:

deoxyadenosine triphosphate (3'"'"'-dATP), deoxyuridine triphosphate (3'"'"'-dUTP), deoxyguanosine triphosphate (3'"'"'-dGTP), deoxycytidine triphosphate (3'"'"'-dCTP), 7-deaza 3'"'"'deoxyadenosine triphosphate (c⁷ -3'"'"'dATP), 7-deaza 3'"'"'deoxyguanosine triphosphate (c⁷ -3'"'"'dGTP) and 7-deaza 3'"'"'deoxy o!inosine triphosphate (c⁷ -3'"'"'dITP).

20. A kit of claim 15, wherein the linkage between the linking group (L) and the linking functionality (L'"'"') is selected from the group consisting of:

a photocleavable bond, a tritylether bond, a β

-benzoylpropionyl group, a levulinyl group, a disulfide bond, an arginine/arginine bond, a lysine/lysine bond, and a pyrophosphate bond and a bond created by Watson-Crick base pairing.

21. A kit of claim 15, wherein the mass modified reagent is modified with a mass-modifying functionality (M) at a heterocyclic base of at least one nucleotide.

22. The kit of claim 21, wherein the heterocyclic base-modified nucleotide is selected from the group consisting of a cytosine nucleotide modified at C-5, a thymine nucleotide modified at C-5, a thymine nucleotide modified at the C-5 methyl group, a uracil nucleotide modified at C-5, an adenine nucleotide modified at C-8, an adenine nucleotide modified at C-7, a c⁷ -deazaadenine modified at C-8, a c⁷ -deazaadenine modified at C-7, a guanine nucleotide modified at C-8, a guanine nucleotide modified at C-7, a c⁷ -deazaguanine modified at C-8, a c⁷ -deazaguanine modified at C-7, a hypoxanthine modified at C-8, a c⁷ -deazahypoxanthine modified at C-7, and a c⁷ -deazahypoxanthine modified at C-8.

23. A kit of claim 15, wherein the mass modified reagent is modified with a mass-modifying functionality (M) attached to one or more phosphate moieties of the internucleotidic linkages of the fragments.

24. A kit of claim 15, wherein the mass modified reagent is modified with a mass-modifying functionality (M) attached to one or more sugar moieties of nucleotides within the set of mass modified base-specifically terminated fragments at at least one sugar position selected from the group consisting of a C-2'"'"' position, an external C-3'"'"' position, and an external C-5'"'"' position.

25. A kit of claim 15, wherein the mass modified reagent is modified with a mass-modifying functionality (M) attached to the sugar moiety of a 5'"'"'-terminal nucleotide and wherein the mass-modifying function (M) is the linking functionality (L).

26. A kit of claim 15, wherein the base-specifically terminated nucleic acid fragments are generated using at least one reagent selected from the group consisting of a nucleic acid primer, a chain-elongating nucleotide, a chain-terminating nucleotide and a tag probe which has been modified with a precursor of the mass-modifying functionality, M;

and a subsequent step comprises modifying the precursor of the mass-modifying functionality, M, to generate the mass-modifying functionality, M, prior to mass spectrometric analysis.